- Filioglou D, Leite GSF, Batatinha H, Santa-Cruz N, Baker FL, Simpson R, Katsanis E. Cytokine-induced memory-like NK cells with tafasitamab show efficacy against B-cell acute lymphoblastic leukemia. Immunother Adv 2025 July 16;5(1):Itaf025. PMID: 40672109; PMCID: PMC12264592
- Filioglou D, Santa-Cruz N, Leite GSF, Davini DW, Cracchiolo MJ, Baker FL, Voudouris V, Husnain M, Simpson RJ, Katsanis E. A Triple oral combination of bendamustine, acalabrutinib, and venetoclax demonstrates efficacy against mantle cell lymphoma in vitro and in vivo. Cancers 2025 Jun 5;17(11):1889. PMID: 40507368; PMCID: PMC12153862
- Smith KA, Batatinha H, Niemiro GM, Baker FL, Zúñiga TM, Diak D, Mylabathula PL, Kistner TM, Davini D, Hoffman E, Colombo J, Seckeler M, Bond RA, Katsanis E, Simpson RJ. Exercise-induced β2-adrenergic receptor activation enhances effector lymphocyte mobilization in humans and suppresses lymphoma growth in mice through NK-cells. Brain Behav Immun2025 Apr; 29:S0889-159(25)00176-X. PMID: 40311885
- Cracchiolo M, Davis L, Matiatos A, Davini D, Husnain M, Simpson RJ, Voudouris V, Katsanis E. Comparable efficacy of oral bendamustine versus intravenous administration in treating hematologic malignancies. Cancer Chemother Pharmacol 2024 Sep;94(3):361-372. PMID: 38878208
- Gilman KE, Matiatos AP, Cracchiolo MJ, Moon AG, Davini DW, Simpson RJ, Katsanis E. Multiagent Intratumoral Immunotherapy Can Be Effective in A20 Lymphoma Clearance and Generation of Systemic T Cell Immunity. Cancers (Basel). 2023 Mar 24;15(7):1951. doi: 10.3390/cancers15071951. PMID: 37046612 Free PMC article.
- Molina MS, Hoffman EA, Stokes J, Kummet N, Simpson RJ, Katsanis E. Murine precursor to type 1 conventional dendritic cells induce tumor cytotoxicity and activation of the PD-1/PD-L1 pathway. Plos One 2022 Aug 18;17(8):e0273075. PMID: 35980974 PMCID: PMC9387840.
- Baker FL, Bigley AB, Agha NH, Pedlar CR, O'Connor DP, Bond RA, Bollard CM, Katsanis E, Simpson RJ. Systemic β-Adrenergic Receptor Activation Augments the ex vivo Expansion and Anti-Tumor Activity of Vγ9Vδ2 T-Cells. Front Immunol. 2019;10:3082. doi: 10.3389/fimmu.2019.03082. eCollection 2019. PubMed PMID: 32038628; PubMed Central PMCID: PMC6993603.
- Bigley AB, Baker FL, Simpson RJ. Cytomegalovirus: an unlikely ally in the fight against blood cancers?. Clin Exp Immunol. 2018 Sep;193(3):265-274. doi: 10.1111/cei.13152. Review. PubMed PMID: 29737525; PubMed Central PMCID: PMC6150251.
- Bigley AB, Rezvani K, Shah N, Sekine T, Balneger N, Pistillo M, Agha N, Kunz H, O'Connor DP, Bollard CM, Simpson RJ. Latent cytomegalovirus infection enhances anti-tumour cytotoxicity through accumulation of NKG2C+ NK cells in healthy humans. Clin Exp Immunol. 2016 Aug;185(2):239-51. doi: 10.1111/cei.12785. PubMed PMID: 26940026; PubMed Central PMCID: PMC4955006.
- Graner MW, Lillehei KO, Katsanis E. Endoplasmic reticulum chaperones and their roles in the immunogenicity of cancer vaccines. Front Oncol. 2015 Jan 6;4:379. doi: 10.3389/fonc.2014.00379. PMID: 25610811; PMCID: PMC4285071.
- Centuori SM, Trad M, LaCasse CJ, Alizadeh D, Larmonier CB, Hanke NT, Kartchner J, Janikashvili N, Bonnotte B, Larmonier N, Katsanis E. Myeloid- derived suppressor cells from tumor-bearing mice impair TGF-β-induced differentiation of CD4+CD25+FoxP3+ Tregs from CD4+CD25-FoxP3- T cells. J Leukoc Biol. 2012 Nov;92(5):987-97. doi: 10.1189/jlb.0911465. Epub 2012 Aug 13. PMID: 22891289; PMCID: PMC3476240.
- Larmonier N, Bonnotte B, Katsanis E. Cytotoxic and antigen presenting functions of T helper-1-activated dendritic cells. Oncoimmunology. 2012 Jul 1;1(4):566-568. doi: 10.4161/onci.19370. PMID: 22754789; PMCID: PMC3382885.
- Janikashvili N, Larmonier N, Katsanis E. Personalized dendritic cell-based tumor immunotherapy. Immunotherapy. 2010 Jan;2(1):57-68. doi: 10.2217/imt.09.78. PMID: 20161666; PMCID: PMC2819192.
- Cantrell J, Larmonier C, Janikashvili N, Bustamante S, Fraszczak J, Herrell A, Lundeen T, J LaCasse C, Situ E, Larmonier N, Katsanis E. Signaling pathways induced by a tumor-derived vaccine in antigen presenting cells. Immunobiology. 2010 Jul;215(7):535-44. doi: 10.1016/j.imbio.2009.09.006. Epub 2009 Oct 31. PMID: 19880213; PMCID: PMC2881173.
- Larmonier N, Fraszczak J, Lakomy D, Bonnotte B, Katsanis E. Killer dendritic cells and their potential for cancer immunotherapy. Cancer Immunol Immunother. 2010 Jan;59(1):1-11. doi: 10.1007/s00262-009-0736-1. Epub 2009 Jul 18. PMID: 19618185.
- Larmonier N, Janikashvili N, LaCasse CJ, Larmonier CB, Cantrell J, Situ E, Lundeen T, Bonnotte B, Katsanis E. Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors. J Immunol. 2008 Nov 15;181(10):6955-63. doi: 10.4049/jimmunol.181.10.6955. PMID: 18981115; PMCID: PMC2579962.
- Larmonier N, Cantrell J, Lacasse C, Li G, Janikashvili N, Situ E, Sepassi M, Andreansky S, Katsanis E. Chaperone-rich tumor cell lysate-mediated activation of antigen-presenting cells resists regulatory T cell suppression. J Leukoc Biol. 2008 Apr;83(4):1049-59. doi: 10.1189/jlb.0907635. Epub 2008 Jan 3. PMID: 18174364.
- Li G, Zeng Y, Chen X, Larmonier N, Sepassi M, Graner MW, Andreansky S, Brewer MA, Katsanis E. Human ovarian tumour-derived chaperone-rich cell lysate (CRCL) elicits T cell responses in vitro. Clin Exp Immunol. 2007 Apr;148(1):136-45. doi: 10.1111/j.1365-2249.2007.03323.x. PMID: 17349014; PMCID: PMC1868858.
- Zeng Y, Chen X, Larmonier N, Larmonier C, Li G, Sepassi M, Marron M, Andreansky S, Katsanis E. Natural killer cells play a key role in the antitumor immunity generated by chaperone-rich cell lysate vaccination. Int J Cancer. 2006 Dec 1;119(11):2624-31. doi: 10.1002/ijc.22150. PMID: 16989012.
- Larmonier N, Marron M, Zeng Y, Cantrell J, Romanoski A, Sepassi M, Thompson S, Chen X, Andreansky S, Katsanis E. Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunol Immunother. 2007 Jan;56(1):48-59. doi: 10.1007/s00262-006-0160-8. Epub 2006 Apr 13. PMID: 16612596.
- Zeng Y, Graner MW, Thompson S, Marron M, Katsanis E. Induction of BCR-ABL- specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells. Blood. 2005 Mar 1;105(5):2016-22. doi: 10.1182/blood-2004-05-1915. Epub 2004 Sep 16. PMID: 15374884; PMCID: PMC1227556.
- Zeng Y, Graner MW, Feng H, Li G, Katsanis E. Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat bcr- abl+ murine leukemia. Int J Cancer. 2004 Jun 10;110(2):251-9. doi: 10.1002/ijc.20115. PMID: 15069690.
- Graner MW, Zeng Y, Feng H, Katsanis E. Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers. Cancer Immunol Immunother. 2003 Apr;52(4):226-34. doi: 10.1007/s00262-002-0359-2. Epub 2003 Feb 18. PMID: 12669247.
- Zeng Y, Feng H, Graner MW, Katsanis E. Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity. Blood. 2003 Jun 1;101(11):4485-91. doi: 10.1182/blood-2002-10-3108. Epub 2003 Feb 6. PMID: 12576309.
- Feng H, Zeng Y, Graner MW, Likhacheva A, Katsanis E. Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate antitumor immunity. Blood. 2003 Jan 1;101(1):245-52. doi: 10.1182/blood-2002-05-1580. Epub 2002 Aug 22. PMID: 12393411.
- Feng H, Zeng Y, Graner MW, Katsanis E. Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T cells. Blood. 2002 Dec 1;100(12):4108-15. doi: 10.1182/blood-2002-05-1389. Epub 2002 Jul 25. PMID: 12393401.
- Feng H, Zeng Y, Whitesell L, Katsanis E. Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity. Blood. 2001 Jun 1;97(11):3505-12. doi: 10.1182/blood.v97.11.3505. PMID: 11369644.
- He L, Feng H, Raymond A, Kreeger M, Zeng Y, Graner M, Whitesell L, Katsanis E. Dendritic-cell-peptide immunization provides immunoprotection against bcr- abl-positive leukemia in mice. Cancer Immunol Immunother. 2001 Mar;50(1):31-40. doi: 10.1007/pl00006680. PMID: 11315508.
